The emerging role of PDE4 inhibitors for the treatment of pulmonary fibrosis
ABSTRACT Introduction Nerandomilast, a phosphodiesterase-4B (PDE4B) preferential inhibitor, was approved in 2025 for the treatment of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). PDE4 enzymes play a central role in regulating intracellular cyclic adenosine monophosphate (cAMP) and are h...